Drug news

Teva files albuterol multi- dose dry powder inhaler at FDA to treat Bronchospasm.

Read time: 1 mins

Last updated:15th Jul 2014

Published:15th Jul 2014

Source: Pharmawand

Teva Pharmaceuticals Industries Ltd., announced that the FDA has accepted for review the company�s new drug application (NDA) for albuterol multi-dose dry-powder inhaler (MDPI), an investigational breath-actuated dry-powder inhaler for the treatment or prevention of Bronchospasm in patients 12 years of age and older with reversible obstructive airway disease; and for the prevention of exercise-induced Bronchospasm (EIB) in patients 12 years of age and older.

A response by the US Food and Drug Administration is expected in March 2015.

Learning Zones

The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.

Click here to view

Related news and insights

Drug news

FDA Advisory Committee meeting to review investigational MDMA-assisted therapy for PTSD

Lykos Therapeutics (formerly MAPS Public Benefit Corporation) announced that on June 4, 2024, the FDA Psychopharmacologic Drugs Advisory Committee ("PDAC") will review data supporting the new drug application ("NDA") for midomafetamine (MDMA) capsules used in combination with psychological intervention ("MDMA-assisted therapy") for adults with post-traumatic stress disorder ("PTSD")

1 mins

Drug news

UCB presents final open-label extension (fenfluramine) data at International Child Neurology Congress (ICNC) Annual Meeting.

UCB announced the final three-year open-label extension (OLE) study results of Fintepla (fenfluramine) in Dravet syndrome are being presented at the International Child Neurology Congress (ICNC), May 6-10, 2024, in Cape Town, South Africa

1 min

Drug news

Lilly statement on FDA Advisory Committee meeting on donanemab for early symptomatic Alzheimer’s disease

The FDA will convene an in-person meeting of the Peripheral and Central Nervous System Drugs Advisory Committee (PCNS) on Monday, June 10, 2024, to discuss donanemab, which Eli Lilly and Company has submitted for the treatment of early symptomatic Alzheimer’s disease. The open public hearing portion of the meeting will be conducted virtually

1 min

See all news